(HealthDay News) – Microarray analysis can be a useful addition to karyotyping in prenatal testing and appears to be helpful in the investigation of stillbirth, according to two studies published in ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

CombiMatrix, a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that it has entered into a strategic partnership with the ...

New York, NY—A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant ...

The field of DNA microarray data analysis is getting increasingly complicated as scientists develop new array technologies and analysis algorithms, yet accurate introductory information on the subject ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

A new test for analyzing the chromosomes of stillborn babies, known as microarray analysis, has now proven 40 percent more effective in pinpointing potential genetic causes of death than the old ...

A new test may be better at detecting potentially harmful genetic changes in children before they are born than current methods, researchers say. The test, called a chromosomal microarray, detected ...

Astra Biotech GmbH is in the pre-launch phase of its newly developed test, based on microarray technology, for rapid simultaneous detection of 25 of the most common mutations causing cystic fibrosis ...